Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Latest News

These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead

Motley Fool • 07/24/2026

Editorial | A true double execution: In Duckett case, justice and truth lie on the gurney

Orlando Sentinel • 07/24/2026

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

GlobeNewswire • 07/23/2026

IBD Live Q&A Summary, Stock Lists For Thursday, July 23, 2026

Investor's Business Daily • 07/23/2026

DAS Technology Unveils Dealer Digital Intelligence (DDI): Next Generation AI-centric Dealer Digital Intelligence to Measure Digital Footprints, AI Search Rankings, and Price Transparency

Business Wire • 07/23/2026